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Abstract
Background: Zoledronic acid, one of the most potent nitrogen-containing biphosphonates, has been demonstrated to have
direct anti-tumor and anti-metastatic properties in breast cancer in vitro and in vivo. In particular, tumor-cell apoptosis has
been recognized to play an important role in the treatment of metastatic breast cancer with zoledronic acid. However, the
precise mechanisms remain less clear. In the present study, we investigated the specific role of large conductance Ca
2+-
activated potassium (BKCa) channel in zoledronic acid-induced apoptosis of estrogen receptor (ER)-negative MDA-MB-231
breast cancer cells.
Methodology/Principal Findings: The action of zoledronic acid on BKCa channel was investigated by whole-cell and cell-
attached patch clamp techniques. Cell apoptosis was assessed with immunocytochemistry, analysis of fragmented DNA by
agarose gel electrophoresis, and flow cytometry assays. Cell proliferation was investigated by MTT test and
immunocytochemistry. In addition, such findings were further confirmed with human embryonic kidney 293 (HEK293)
cells which were transfected with functional BKCa a-subunit (hSloa). Our results clearly indicated that zoledronic acid directly
increased the activities of BKCa channels, and then activation of BKCa channel by zoledronic acid contributed to induce
apoptosis in MDA-MB-231 cells. The possible mechanisms were associated with the elevated level of intracellular Ca
2+ and
a concomitant depolarization of mitochondrial membrane potential (Dym) in MDA-MB-231 cells.
Conclusions: Activation of BKCa channel was here shown to be a novel molecular pathway involved in zoledronic acid-
induced apoptosis of MDA-MB-231 cells in vitro.
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Introduction
Breast cancer is the most common neoplasm in women and has
a strong propensity to metastasize to bone. Most patients with
advanced breast cancer frequently develop bone metastases
characterized with the increased osteoclastic bone resorption,
and at this stage, the disease associated with pain, fractures, and
hypercalcemia is considered incurable [1]. More recently, multiple
preclinical and early clinical studies have demonstrated that
bisphosphonates are successfully established drugs that reduce the
incidence of hypercalcaemia and skeletal morbidity in the
treatment of breast cancer and bone metastasis [2]. The clinical
potential of zoledronic acid, one of the most potent nitrogen-
containing biphosphonates, is widely confirmed in the adjuvant
and neoadjuvant settings of treatment for metastatic breast cancer
[3,4]. Zoledronic acid has been reported not only to inhibit
osteoclast-mediated bone resorption, but also have direct anti-
tumor and anti-metastatic properties in breast cancer in vitro and in
vivo [4]. The primary mechanisms responsible for the direct anti-
tumor activity of zoledronic acid may involve the inhibition of
tumor-cell proliferation, the induction of tumor-cell apoptosis and
autophagy, the prevention of tumor-cell invasion and adhesion in
bone, the reduction of angiogenesis, and the stimulation of innate
anti-cancer immunity [2,4,5]. In particular, tumor-cell apoptosis is
an active, gene-regulated cell death, which has been considered to
play a pivotal role in the treatment of breast cancer with
zoledronic acid [2,4,5,6]. However, the precise mechanisms by
which zoledronic acid induces apoptosis in breast cancer cells
remain to be determined [7].
Apoptosis is characterized by a distinct series of morphological
and biochemical changes that result in cell shrinkage, DNA
breakdown and phagocytic death. There are at least two
regulatory pathways that can lead to apoptosis [8]. The extrinsic
pathway (or the death receptor pathway) involves the binding of
apoptotic signals to a death receptor and subsequent caspase
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triggered by the depolarization of mitochondrial membrane or
DNA damage, which relies on the disruption of the mitochondrial
membrane. Recently, many studies suggested that large conduc-
tance Ca
2+-activated K
+ (BKCa) channels are involved in the
regulation of apoptosis. BKCa channels are ubiquitously present in
most human cells and play an essential role in the regulation of
basic cellular processes [9,10]. The basic functional unit of BKCa
channel is the pore forming a-subunit encoded by a single gene,
Sloa or KCNMA1.B K Ca channels are activated by membrane
potential, intracellular Ca
2+, and phosphorylation. Activation of
BKCa channel hyperpolarizes the membrane potential and
deactivates the voltage-dependent Ca
2+ channels (VDCCs), which
leads to a reduction in intracellular Ca
2+ concentration. In
excitable cells, such as vascular smooth muscle cells (VSMCs), it is
well known that BKCa channels contribute to the regulation of
vascular tone in a negative feedback manner which limits VSMCs
depolarization and prevents vasospasm [11]. Recently, activation
of BKCa channel has also been reported to be involved in the
regulation of apoptosis besides its electrophysiological function in
vascular relaxation [12,13]. In contrast, functions of the BKCa
channel in non-excitable cells are somewhat enigmatic. Previous
studies have implicated a role for the BKCa channel in the
progression of several malignant tumors, including metastatic
breast cancer [14,15,16], osteosarcoma [17], prostate cancer
[18,19], colorectal carcinogenesis [20], ovarian cancer [21], and
glioma [22,23,24,25]. In particular, it has been demonstrated that
BKCa channels are highly expressed in various established human
breast cancer cell lines, such as MCF-7, MDA-MB-231, MDA-
MB-468, MDA-MB-435s, and MDA-MB-361 [26,27]. However,
the role of BKCa channel in phenomena related to breast cancer is
still controversial. For example, activation of BKCa channel has
been described to be involved in the proliferation [14,16,26],
migration, and invasion [15] of breast cancer cells. In contrast,
some work also suggested that BKCa channel might have no roles
in the controlling growth of breast cancer cells because the specific
BKCa channel blockers [charybdotoxin or iberiotoxin (IBTX)] did
not have any effect on cell proliferation [27]. However, to date
there have been no studies addressing the possibility of BKCa
channel involvement in the regulation of apoptosis in human
breast cancer cells.
The purpose of this study was to examine the specific role of
BKCa channel in zoledronic acid-induced apoptosis of breast
cancer cells. The ER-negative MDA-MB-231 cell lines were
chosen for the experiment. The action of zoledronic acid on BKCa
channel was investigated by whole-cell and cell-attached patch
clamp techniques. Cell apoptosis was assessed with immunocyto-
chemistry, analysis of fragmented DNA by agarose gel electro-
phoresis, and flow cytometry assays. Cell proliferation was
investigated by MTT test and immunocytochemistry. In addition,
such findings were further confirmed from human embryonic
kidney 293 (HEK293) cells which were transfected with functional
BKCa a-subunit (hSloa). Finally, intracellular Ca
2+ and mitochon-
drial membrane potential (Dym) in MDA-MB-231 cells were also
examined to investigate the possible mechanisms. Evidence
obtained in the present study suggests that zoledronic acid directly
increased the activities of BKCa channels, and then activation of
BKCa channel by zoledronic acid contributed to induce apoptosis
in ER-negative MDA-MB-231 breast cancer cells. The possible
mechanisms were associated with the elevated level of intracellular
Ca
2+ with a concomitant depolarization of Dym in MDA-MB-231
cells. Our data are the first to show involvement of BKCa channel
activation in zoledronic acid-induced apoptosis of of ER-negative
breast cancer cells in vitro.
Results
Zoledronic acid induced apoptosis in MDA-MB-231
breast cancer cells
Treatment with zoledronic acid for 48 h significantly induced
apoptosis in MDA-MB-231 cells with its typical characteristics of
nuclear condensed or fragmented (Figure 1A) as well as its
positive-staining for TUNEL (Figure 1B). Apoptotic MDA-MB-
231 cells in response to zoledronic acid were dose-dependent with
an EC50 of ,17 mM (Figure 1C) and time-dependent (Figure 1D).
The apoptotic effects of zoledronic acid seemed to be maximized
at the concentration of 100,1000 mM. As compared with vehicle
controls, the administration of 100 mM zoledronic acid for 48 h
induced a lower rate of necrotic cell death (5.5662.65% versus
1.2360.6%). However, the administration of 1000 mM zoledronic
acid for 48 h not only induced a significant increase in apoptotic
rates (28.1661.54% versus 1.5560.84%, Figure 1C), but also
induced a higher rate of necrotic cell death (red fluorescent
chromatin, 25.1261.87% versus 1.2360.6%), which indicated the
cytotoxic effects of zoledronic acid at high concentration.
Therefore, 100 mM zoledronic acid was selected as the working
concentration to induce apoptosis (Figure 1C). In addition,
administration of 100 mM zoledronic acid for only 8 h could
significantly increased the percentage of apoptotic nuclei from
1.3661.20% to 10.1361.15%, and the apoptotic effects appeared
to be maximized (to 25.1761.57%) at about 48 h during our
observation (Figure 1D). Our results that zoledronic acid
significantly induced apoptosis of MDA-MB-231 breast cancer
cells are consistent with a previous report [6].
Augmenting effects of zoledronic acid on BKCa channel
activity in MDA-MB-231 breast cancer cells
Whole-cell currents in MDA-MB-231 cells showed time- and
voltage-dependent outward-currents (the left panel of Figure 2).
Acute extracellular application of 30 mM NS1619, the specific
agonist of BKCa channel, significantly and reversibly amplified the
whole-cell currents by 2-fold as compared with the control at the
testing potential of +60 mV. Subsequently, extracellular applica-
tion of 1 mM tetraethylammonium (TEA, the nonselective BKCa
inhibitor) or 100 nM IBTX (the specific BKCa blocker) signifi-
cantly reduced the outward-current amplitudes and diminished
the current noise associated with higher positive command
potentials. NS1619 has been reported to be highly selective for
activating BKCa channels through a-subunit [10]. TEA pre-
dominantly blocks BKCa channel currents at doses of #1m M
[32]. The current-voltage relationship (I-V) curves were generated
by plotting currents against command potentials (the right panel of
Figure 2). These results clearly identified the properties of BKCa
currents recorded from MDA-MB-231 cells, which were in
agreement with previous report [27].
Experiments were then undertaken to determine the action of
zoledronic acid on BKCa channels in MDA-MB-231 cells. Acute
addition of 100 mM zoledronic acid to the bathing solution led to
a significant increase in whole-cell outward currents (the left panel
of Figure 3A). For example, at the testing potential of +60 mV,
zoledronic acid significantly increased outward-current densities
by 2.5-fold as compared with the control. However, acute
application of 100 nM IBTX in the continued presence of
zoledronic acid significantly reduced whole-cell currents. The
mean I-V relationships were further expressed in terms of current
densities (the right panel of Figure 3A). Additional experiments
were performed to determine whether zoledronic acid affects
BKCa single-channel activity in MDA-MB-231 cells. The repre-
sentative traces of single-channel current were obtained at
BKCa Channel and Zoledronic Acid
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of 100 mM zoledronic acid to the bath solution (Figure 3B).
Zoledronic acid significantly increased open probability (Po)b y3 -
fold at +40 mV (Figure 3C) but had no effects on unitary current
amplitude (Am) (Figure 3D). Taken together, these observations
clearly indicated that zoledronic acid increased the whole-cell and
single-channel activities of BKCa channel recorded from MDA-
MB-231 cells, which has not been reported previously in breast
cancer cells.
Activation of BKCa channel by zoledronic acid induced
apoptosis in MDA-MB-231 breast cancer cells
To investigate the role of BKCa channels in zoledronic acid
induced-apoptosis, Hoechst33342+ PI double-staining (Figure 4A),
analysis of fragmented DNA (Figure 4B), and flow cytometry
assays (Figure 4C) were used to evaluate apoptosis of MDA-MB-
231 breast cancer cells. Treatment with 100 mM zoledronic acid
for 48 h significantly caused about 24.6563.25% cells to undergo
apoptosis (Figure 4A). However, application of BKCa channel
blocker (1 mM TEA or 100 nM IBTX) to the culture medium in
the presence of zoledronic acid for 48 h could partially reverse
zoledronic acid-induced apoptosis to 10.7761.69% or
12.4662.29%, respectively. In contrast, treatment with 1 mM
TEA or 100 nM IBTX for 48 h alone did not induce significant
apoptosis as compared with the control, respectively. Treatment
with the specific agonist of BKCa channel (30 mM NS1619) for
48 h alone induced apoptosis to 15.4463.57%, similar to the
apoptotic effects of zoledronic acid (Figure 4A). To independently
verify apoptosis qualitatively, fragmented DNA was analyzed by
agarose gel electrophoresis, which is considered to be a biochemical
hallmark for apoptosis. These characteristic changes associated
with apoptosis are due to the activation of a family of intracellular
caspases [12]. Treatment with 100 mM zoledronic acid or 30 mM
NS1619 for 48 h could form a detectable ladder of multiples of
180–200 bp associated with the DNA fragmentation pattern in
MDA-MB-231 cells (Figure 4B). However, application of 1 mM
TEA or 100 nM IBTX to the culture medium in the presence of
zoledronic acid for 48 h could also induce a detectable ladder but
much fainter when compared to the treatment with zoledronic
acid, which suggested that TEA or IBTX could partially reverse
the apoptotic effects of zoledronic acid (Figure 4B). Lastly, we
performed flow-cytometric analyses (Annexin V + PI double-
binding) to confirm and quantify the induction of apoptosis in
MDA-MB-231 cells. Treatment with 100 mM zoledronic acid or
30 mM NS1619 for 48 h significantly induced apoptosis in MDA-
MB-231 breast cancer cells (Figure 4C, lower right quadrants).
Figure 1. Apoptotic effects of zoledronic acid on MDA-MB-231 cells. (A) Nuclear condensation and fragmentation of single cell were shown
with representative Hoechst33342 + PI double-staining. Arrow indicated the apoptotic nuclei and arrowhead indicated the necrotic nuclei. (B)
Positive transferase-mediated nick-end labeling (TUNEL)-stained nuclei were used in some experiments. (C) Dose-dependent curve is shown for the
apoptotic effects of zoledronic acid concentration (0–1000 mM) for 48 h. (D) Time-dependent curve is shown for the apoptotic effects of 100 mM
zoledronic acid (D). Values are means 6 SE; n=40,80 fields of cells in 8 independent experiments for each data point. (Scale bar in A and B: 25 mm)
doi:10.1371/journal.pone.0037451.g001
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induced apoptosis. These observations from Annexin V + PI
double-binding (Figure 4C) were in accordance with results from
Hoechst33342 + PI double-staining (Figure 4A) or analysis of
fragmented DNA (Figure 4B). These findings obviously indicated
that activation of BKCa channel by zoledronic acid induced
apoptosis in MDA-MB-231 breast cancer cells.
Activation of BKCa channel by zoledronic acid suppressed
proliferation of MDA-MB-231 breast cancer cells
To evaluate the role of BKCa channel in zoledronic acid-
inhibited cell growth, MTT assays (Figure 5A) and PCNA-staining
(Figure 5B and Figure 5C) were used to assess cell viability and
proliferation in MDA-MB-231 breast cancer cells. Treatment with
100 mM zoledronic acid or 30 mM NS1619 for 48 h not only
exhibited a strong inhibitory action on cell survival (Figure 5A),
but also significantly decreased the percentage of PCNA-positive
cells as compared with the control (Figure 5B and Figure 5C). As
a marker of cell proliferation, PCNA is associated with rapidly
dividing cells. In the present study, NS1619 significantly reduced
the proliferation of MDA-MB-231 cells, which was consistent with
previous report [27]. However, TEA or IBTX, the blockers of
BKCa channel, could partially reverse the anti-proliferative effects
of zoledronic acid in MDA-MB-231 cells. In contrast, TEA or
IBTX alone did not change cell viability and proliferation in
MDA-MB-231 cells. These observations indicated that activation
of BKCa channel by zoledronic acid significantly attenuated the
proliferation of MDA-MB-231 cells.
Activation of cloned BKCa channels by zoledronic acid
induced apoptosis in transfected HEK293 cells
It has been demonstrated that endogenous currents are
generally small and there are almost no endogenous BKCa
currents in native HEK293 cells [28,29]. Therefore, HEK293
cells were used to investigate the exogenous BKCa channels in
isolation by removing other types of channel currents which can
potentially contaminate BKCa currents in native MDA-MB-231
cells. Cloned BKCa a-subunit (hSloa) were transiently transfected
into HEK293 cells. I-V curves clearly identified that activities of
cloned BKCa channel were augmented by acute application of
100 mM zoledronic acid and blocked by extracellular application
of 100 nM IBTX in HEK-hSloa cells (Figure 6A). Double-staining
of Hoechst33342 + PI (Figure 6B and Figure 6C) showed that
treatment with 100 mM zoledronic acid or 30 mM NS1619 for
24 h significantly induced 26.2463.25% or 18.3863.57% apo-
ptosis of HEK-hSloa cells as compared with the control
(4.1862.39%). However, the blocker of BKCa channel, 1 mM
TEA or 100 nM IBTX could completely reverse zoledronic acid-
induced apoptosis in HEK-hSloa cells. In contrast, treatment with
1 mM TEA or 100 nM IBTX did not significantly induce
apoptosis of HEK-hSloa cells as compared with the control. In
another experiment, we also found that zoledronic acid had no
apoptotic effects in nontransfected HEK293 cells (4.5160.65% in
zoledronic acid vs. 3.4561.39% in the control). These results
suggested that zoledronic acid-induced apoptosis of HEK-hSloa
cells was mainly due to its activation of cloned BKCa channels and
BKCa a-subunit may be a target for the action of zoledronic acid.
Figure 2. Representative families of whole-cell outward currents recorded from MDA-MB-231 cells without BKCa channel
modulators, in the presence of agonist NS1619, or antagonist TEA and IBTX to the bath solution. In whole-cell configuration, membrane
potential was held at 260 mV and stepped at 15-s intervals to potentials between 250 mV and +80 mV in 10-mV increments for 200 ms and then
held at +30 mV for 20 ms. Average data are shown by means 6 SE with the number of cells recorded in parentheses in I-V curves which are shown
for each condition in the right panel.
doi:10.1371/journal.pone.0037451.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37451Figure 3. Actions of zoledronic acid on BKCa whole-cell and single-channel activities in MDA-MB-231 cells. (A) Representative families
of BKCa whole-cell currents in MDA-MB-231 cells before and after application of 100 mM zoledronic acid. Application of 100 nM IBTX in the continued
presence of zoledronic acid significantly inhibited BKCa whole-cell currents. The mean I-V curves were further expressed in terms of current densities.
(B) Representative traces of BKCa single-channel currents in cell-attached patches before and after application of 100 mM zoledronic acid to the bath
solution. In cell-attached patches, the membrane voltage was held at +40 mV and the Ca
2+ concentration in the bath fluid was 1.98 mM. (C) Plots of
open probability (Po) and unitary current amplitude (Am)i nB K Ca channels were shown against membrane potentials. Values are means 6 SE with the
number of cells examined is in parentheses. *P,0.05 as compared with the control by ANOVA. (O: open state; C: close state)
doi:10.1371/journal.pone.0037451.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37451Figure 4. Activation of BKCa channel by 100 mM zoledronic acid induced apoptosis of MDA-MB-231 cells. (A) Summarized data from
Hoechst33342 + PI double-staining showed the percentage of apoptotic rates in MDA-MB-231 cells treated with different conditions. Values are
means 6 SE. n= 40,60 fields of cells in 8 independent experiments for each data point. Apoptosis of MDA-MB-231 cells were analyzed by agarose
gel electrophoresis (B) and Annexin V + PI double-binding from cytometry (C). In the dot plots of Annexin V + PI double-binding, viable cells (Annexin
V-low/ PI-low) are found in the lower left quadrant, apoptotic cells (Annexin V-high/ PI-low) in the lower right, postapoptotic secondary necrotic cells
(Annexin V-high/ PI-high) in the upper right and primary necrotic cells (Annexin V-low PI-high) in the upper left. Numbers in each quadrant are
percentage of cells they contain. Images in (B) and (C) represent 3 and 5 independent experiments, respectively. *P,0.05 as compared with the
control; #P,0.05 as compared with the treatment of zoledronic acid.
doi:10.1371/journal.pone.0037451.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37451Figure 5. Activation of BKCa channel by 100 mM zoledronic acid suppressed proliferation of MDA-MB-231 cells. (A) Summarized data
from MTT assays showed global cell viabilities in MDA-MB-231 cells treated with different conditions. Values are means 6 SE in 6 independent
experiments for each data point. (B) Representative proliferating cell nuclear antigen (PCNA)-positive nuclei were shown with arrow indication. (C)
Summarized data from PCNA staining showed the percentage of proliferative rates in MDA-MB-231 cells treated with different conditions. Values are
means 6 SE; n= 30,50 fields of cells in 5 independent experiments for each data point. *P,0.05 as compared with the control; #P,0.05 as
compared with the treatment of zoledronic acid. (Scale bar in B: 25 mm).
doi:10.1371/journal.pone.0037451.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37451Figure 6. Activation of cloned BKCa channel by zoledronic acid induced apoptosis in HEK-hSloa cells. (A) Representative families of BKCa
whole-cell currents in HEK-hSloa cells before and after application of 100 mM zoledronic acid. Application of 100 nM IBTX in the continued presence
of zoledronic acid significantly inhibited cloned BKCa whole-cell currents. The mean I-V curves were further expressed in terms of current densities. (B)
Representative Hoechst33342 + PI double-staining showed the apoptotic nuclei with arrow indications and necrotic nuclei with arrowhead indication
in HEK-hSloa cells. (C) Summarized data showed the percentage of apoptotic rates in HEK-Sloa cells treated with different conditions. Values are
means 6 SE; n=20,30 fields of cells in 5 independent experiments for each data point. *P,0.05 as compared with control. (Scale bar in B: 25 mm).
doi:10.1371/journal.pone.0037451.g006
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37451Figure 7. Activation of BKCa channel by zoledronic acid elevated the level of intracellular Ca
2+ fluorescence intensity in MDA-MB-
231 cells. (A) Representative Fluo-3/AM fluorescence intensities recorded in MDA-MB-231 cells before and after applications of TEA, IBTX, zoledronic
acid, and NS1619. (B) Summarized data showed the average changes of Fluo-3/AM fluorescence intensities in MDA-MB-231 cells treatment with
BKCa Channel and Zoledronic Acid
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apoptosis was associated with the elevated level of
cytosolic free Ca
2+ and the depolarized mitochondrial
membrane potential (Dym) of MDA-MB-231 breast
cancer cells
To evaluate the possible mechanisms, the intracellular free Ca
2+
([Ca
2+]i) and mitochondrial membrane potential (Dym) of MDA-
MB-231 cells were measured before and after applications of TEA,
IBTX, zoledronic acid, and NS1619, respectively. The present
data showed that 100 mM zoledronic acid evoked a transient peak
increase of [Ca
2+]i (at 60 ,80 s) and was followed by a sustained
increase in [Ca
2+]i (at 120 ,180 s) that was above the basal values
in the continued presence of zoledronic acid (Figure 7A).
Compared to the control, zoledronic acid significantly elevated
the level of [Ca
2+]i by 66.7% in MDA-MB-231 cells (Figure 7B),
which were consistent with previous report that zoledronic acid
could increase [Ca
2+]i in human osteosarcoma cells probably
owing to the release of Ca
2+ from intracellular stores [34].
Furthermore, as compared with the control, zoledronic acid also
induced a stronger mitochondrial depolarization of MDA-MB-231
cells indicated with obvious green fluorescence at 90 s and 180 s of
scanning duration (Figure 8), which were in accordance with
previous report that zoledronic acid gradually induces a decrease
of Dym in MCF-7 breast cancer cells and RPMI 8226 myeloma
cells [35]. In addition, 30 mM NS1619 also significantly also
evoked a significant augmentation of [Ca
2+]i by ,46.2% and
a stronger depolarization of Dym as compared with the control.
However, 1 mM TEA or 100 nM IBTX could partially reverse
the effects of zoledronic acid on [Ca
2+]i (Figure 7) and de-
polarization of Dym (Figure 8) in MDA-MB-231 cells, re-
spectively. In contrast, only TEA or IBTX showed a reduced
(but not significant) induction of [Ca
2+]i (Figure 7) and did not
significantly change the Dym (Figure 8). These results suggested
activation of BKCa channel in zoledronic acid-induced apoptosis
was associated with elevated levels of cytosolic free Ca
2+ and the
depolarization of Dym in MDA-MB-231 breast cancer cells.
Discussion
The present study makes two novel findings. Firstly, zoledronic
acid directly activated BKCa channel, and then activation of BKCa
channels by zoledronic acid was involved in initiating apoptosis of
ER-negative MDA-MB-231 breast cancer cells in vitro. Such
conclusions were further confirmed from HEK293 cells trans-
fected with cloned BKCa a-subunit. Secondly, the possible
mechanisms of activation of BKCa channels in zoledronic acid-
induced apoptosis were associated with the increased intracellular
Ca
2+ and a concomitant depolarization of mitochondrial mem-
brane potential in MDA-MB-231 breast cancer cells. Our study
provided a novel molecular pathway whereby activation of BKCa
channel by zoledronic acid induced apoptosis of ER-negative
breast cancer cells in vitro.
Bisphosphonates are synthetic derivates of endogenous pyr-
ophosphates in which the central atom of oxygen has been
replaced by a carbon atom. In vivo, bisphosphonates bind strongly
to hydroxyapatite on the bone mineral surface with high affinity
and are preferentially delivered to sites of increased bone
formation or resorption [2,4]. Zoledronic acid, a cyclic bispho-
sphonate of the third generation, contains a nitrogen atom in an
imidazole ring. It has been considered that zoledronic acid is the
most potent anti-resorptive compounds to lower the serum
calcium concentration (hypercalcaemia) and reduce the excessive
bone loss and fracture risk associated with malignant skeletal
diseases [2,3,4]. In addition, emerging evidence also suggests
a beneficial preventive treatment of zoledronic acid in patients
with early stages of breast cancer without bone metastases [36,37].
Laboratory studies suggest that zoledronic acid can also directly
induce important anti-tumour effects in breast cancer by inhibiting
cell adhesion and invasive potential, suppressing cell proliferation,
and inducing tumor-cell apoptosis [2,4,6]. In particular, it has
been recognized that tumor-apoptosis plays an important role in
the treatment of breast cancer with zoledronic acid [4,5].
However, the underlying mechanisms of action by which
zoledronic acid induces apoptosis in breast cancer cells remain
less clear. One possible mechanism is that zoledronic acid inhibits
farnesyl pyrophosphate synthase (FPPS), a key enzyme in the
mevalonate pathway, which results in decreased isoprenoid
production and protein prenylation, and then affects the in-
tracellular signaling pathways, such as failure to activate small
GTPases (Ras and Rho), down-regulation of avb3/avb5 integrins,
and releasing cytochrome C into the cytosol with subsequent
activation of the caspase cascade [4,37]. Another possible
mechanism is that inhibition of FPPS also causes accumulation
of ATP analogues (Apppi), which can directly induce apoptosis by
disrupting mitochondrial ATP/ADP translocase [4,35]. In agree-
ment with previous reports [1,6], we observed that zoledronic acid
significantly increased apoptosis in a concentration and time
dependent manner in MDA-MB-231 cells (Figure 1). It is
considered that the net apoptotic effects of zoledronic acid on
breast cancer cells are determined by a variety of pathways [3,4,5].
Therefore, we explored the novel mechanisms pathways to explain
the possible mechanisms of zoledronic acid induced-apoptosis.
In the present study, we demonstrated that zoledronic acid
significantly increased activities of BKCa channel (Figure 3), and
then, activation of BKCa channels by zoledronic acid significantly
induced apoptosis (Figure 4) and suppressed cell proliferation
(Figure 5) in MDA-MB-231 breast cancer cells. However, blocking
BKCa channels by 1 mM TEA or 100 nM IBTX could partially
reverse apoptotic effects and anti-proliferative effects of zoledronic
acid in MDA-MB-231 breast cancer cells. Such conclusions were
further confirmed from the cloned BKCa channels in HEK-hSloa
cells (Figure 6). These observations strictly indicated that activation
of BKCa channel by zoledronic acid induced apoptosis in ER-
negative MDA-MB-231 breast cancer cells.
To date, it is notable that a controversial role for BKCa channels
has been reported in carcinogenesis in vivo and in vitro. Some
studies have suggested that BKCa channels contributed to the high
proliferative or invasive potential in a number of malignant cell
lines, such as non-metastatic (MCF-7) breast cancer cells [14,26],
brain-specific metastatic (MDA-MB-361) breast cancer cells [15],
human prostate cancer [19], colorectal carcinogenesis [20], glioma
[24,25]. However, more recent publications put forward the
opposite idea that BKCa channels are not required for the
proliferation in glioma [22] or breast cancer cells [27]. What is
more, BKCa channels have been reported to exhibit anti-
proliferative and anti-tumorogenic properties in osteosarcoma
cells [17], ovarian cancer cells [21], and glioma cells [23]. In the
present study, we reported that BKCa channel directly participated
in the regulation of zoledronic acid-induced apoptosis in human
different conditions during 120 ,180 s. Values are means 6 SE with the number of cells recorded in parentheses. *P,0.05 as compared with the
control; #P,0.05 as compared with the treatment of zoledronic acid.
doi:10.1371/journal.pone.0037451.g007
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apparent discrepancy between these studies may be explained by
distinct roles of BKCa channels in different cancer cell lines and
different tumor microenvironment [17,22].
It is believed that different breast cancer cell lines have distinct
properties, so the results of BKCa channels from MDA-MB-231
breast cancer cell line in vitro may not be generalized to the other
breast cancer cell lines. For example, we also observed the role of
BKCa channels in zoledronic acid-induced apoptosis in MCF-7
cells. Unlike apoptosis in MDA-MB-231 cells, zoledronic acid-
induced apoptosis in MCF-7 cells was resistant to BKCa channels
blockers. Interestingly, when MCF-7 cells were treated with the
ER inhibitor ICI182780, zoledronic acid-sensitive apoptosis
regained its partial sensitivity to BKCa channel inhibitors (data
not shown). It remains unclear why these differences exist and
required further investigations.
Taken together, our work reported in vitro evidence that
zoledronic acid directly increased the activities of BKCa channel,
and then activation of BKCa channel by zoledronic acid may be
partially responsible for zoledronic acid induced-apoptosis in MD-
MBA-231 breast cancer cells. Such conclusion was further
supported from HEK293 cells transfected with cloned BKCa
channels. The possible mechanisms were associated with the
elevation of intracellular Ca
2+ and the depolarization of Dymi n
MD-MBA-231 breast cancer cells. Therefore, the new recognition
of zoledronic acid on BKCa channels may offer opportunities to
develop a novel pharmacological approach in the treatment of
breast cancer.
Figure 8. Activation of BKCa channel by zoledronic acid depolarized mitochondrial membrane potentials (Dym) of MDA-MB-231
cells. (A) Representative fluorescent images of MDA-MB-231 cells stained with JC-1 probe in different groups (Scale bar: 16 mm). (B) Quantitative
analysis of the shift of mitochondrial orange-red fluorescence in different groups at 0 s, 90 s, and 180 s, respectively. The average fluorescence
intensities are expressed as the ratio of green to red fluorescence. An increase in the bar indicated a shift in the fluorescence ratio correlating witha n
increase in mitochondrial depolarization. Values are means 6 SE with the number of cells recorded in parentheses. *P,0.05 as compared with the
control; #P,0.05 as compared with the treatment of zoledronic acid at 90 s and 180 s.
doi:10.1371/journal.pone.0037451.g008
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Chemicals and reagents
Zoledronic acid (Zometa, Novartis Pharmaceuticals Corp,
Shwewiz AG, Switzerland) was provided as the hydrated disodium
salt and dissolved in dH2O. Unless otherwise stated, chemicals
used in this study were obtained from Sigma Chemical Company
(St. Louis, MO).
Cell culture and transfection
MDA-MB-231 breast cancer cell line and HEK293 cells were
purchased from the American Type Culture Collection (ATCC;
Manassas, VA). MDA-MB-231 and HEK293 cells were cultured
at 37uC and 5% CO2 in DMEM (Gibco BRL, Grand Island, NY)
supplemented with 5% and 10% FBS (HyClone, Logan, UT),
respectively. The hSloa cDNA plasmid was cloned in the
expression vector pIRES (Clontech Laboratories, Palo Alto, CA;
pIRES-hSloa). The transfection was performed by Lipofectami-
ne
TM 2000 (Invitrogen, Carlsbad, CA) as described before [28,29].
To diminish the influence of serum on cell growth, cells were
cultured in 1% FBS +1% Insulin-Transferrin-Selenium (ITS)
during the pharmacological experiments.
Electrophysiological measurements
Whole-cell and single-channel of BKCa currents were recorded
with an amplifier (CEZ-2300, Nihon Kohden Co., Tokyo, Japan)
and a version interface (Axon Instruments, Foster City, CA) as
reported previously [13,30,31]. Whole-cell BKCa currents were
recorded with the conventional voltage clamp configuration.
Current densities were obtained by normalizing currents to the cell
membrane capacitance (Cm). The extracellular (bath) solution
contained 135 mM NaCl, 5.0 mM KCl, 1.8 mM CaCl2, 1.0 mM
MgCl2, 10 mM HEPES, 10 mM glucose, and 5.0 mM 4-
aminopyridine (4-AP), equilibrated with 95% O2 and 5% CO2
at pH 7.4 adjusted by NaOH. 4-AP in the bath solution was used
to exclude the interference from voltage-dependent K
+ (KV)
channel currents [32]. The internal (pipette) solution contained
50 mM KCl, 70 mM K-Asp, 8.0 mM NaCl, 2.0 mM MgCl2,
1.0 mM Na2ATP, 0.5 mM GTP, 10 mM HEPES, 1.0 mM
CaCl2, 2.0 mM EGTA equilibrated with 95% O2 and 5% CO2
at pH 7.2 titrated with KOH.
Single-channel currents of BKCa were recorded in cell-attached
membrane patches. The pipette (external) solution contained
40 mM K-Asp, 100 mM KCl, 1.0 mM CaCl2, 10 mM HEPES
equilibrated with 95% O2 and 5% CO2 at pH 7.4 titrated with
KOH. The bath solution contained 100 mM K-Asp, 40 mM KCl,
10 mM HEPES, 2.0 mM EGTA, 1.98 mM CaCl2 equilibrated
with 95% O2 and 5% CO2 at pH 7.4 titrated with KOH.
Apoptosis assays
Morphological assessment of apoptotic cells. Two fluo-
rescent nuclear binding dyes, Hoechst33342 and propidium iodine
(PI) were added to the culture medium to a final concentration of
5 mg/ml. Cells were evaluated by fluorescence microscopy
according to the following grading system: normal nuclei (blue
chromatin with organized structure), apoptotic cells (bright
fluorescent chromatin which is highly condensed or fragmented),
and necrotic cells (red fluorescent chromatin) as described
previously [28,29]. The apoptotic index was calculated as (number
of apoptotic cells/total cells counted) 6100%. Scoring was done
blindly.
In some experiments, Terminal deoxynucleotidyl transferase-
mediated dUTP Nick End labeling (TUNEL) assay was performed
to detect apoptosis with the in situ DeadEnd
TM Colorimetric
TUNEL System (Promega, USA) [13,28,29]. Briefly, fragmented
DNA was nick end-labeled with a mixture of Terminal
Deoxynucleotidyl Transferase, Recombinant (rTdT) enzyme and
Biotinylated Nucleotide Mix in an Equilibration Buffer. The
reaction was stopped and horseradish peroxidase-labeled strepta-
vidin (Streptavidin HRP) was then bound to the biotinylated
fragmented DNA, which was detected using the peroxidase
substrate, hydrogen peroxide, and the stable chromogen, diami-
nobenzidine (DAB).
Analysis of fragmented DNA by agarose gel
electrophoresis. DNA fragmentation assay was performed
using the previously described methods with some revisions
[28,29]. Briefly, cells were lysed with buffer containing 10 mM
Tris-HCl, 10 mM EDTA, and 0.5% Triton X-100 at pH 7.6
titrated with Tris base (pH 8.0). The fragmented DNA was
extracted with phenol/chloroform/isopropanol (25:24:1, v/v) and
then extracted again with chloroform/isopropanol (24:1, v/v). The
DNA fragments were separated by 2% agarose gel electrophoresis.
Flow cytometry assays for apoptotic cell death. Cells
were harvested and incubated with FITC-labeled Annexin V
(Merck Biosciences, Bad Soden, Germany) and the DNA-binding
dye, PI. The percentage of apoptotic and necrotic cells were
determined by flow cytometry (FACScalibur, Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA). Five parallel
samples were measured and ten thousand events were analyzed
using the Cell Quest Pro software (Becton Dickinson Immuzole-
dronic acidcytometry System).
Proliferation assays
MTT assays for cell viability. After incubation with MTT
(5 mg/ml), cells were treated with DMSO to dissolve the purple
formazan crystals formed [28,29]. The optical density was
recorded using a micro-plate reader (mQuant, Bio-Tek Instru-
ments, Inc., USA) at 490 nm. The cell viability was calculated by
dividing the optical density of samples with the optical density of
solvent control.
Proliferating cell nuclear antigen (PCNA) staining. As
previous described [29], fixed cells were incubated with a 1:50
dilution of the mouse anti-human PCNA monoclonal antibody
(Santa Cruz, USA) and then incubated with the biotinylated goat
anti-mouse IgG in a dilution of 1:200 (Santa Cruz, USA). Finally,
the ready-to-use streptavidin-horseradish-peroxidase complex
conjugated avidin biotin complex (1:100) (Santa Cruz, USA) was
applied and the peroxidase colour reaction was started by
incubation with 0.04% (w/v) DAB. The proliferative index was
calculated as (number of proliferative cells/total cells counted)
6100%. Scoring was done blindly.
Measurement of intracellular Ca
2+. As previous described
[29,31,33], cells were incubated with Fluo-3-acetoxymethyl ester
(Fluo-3/AM, Invitrogen, USA) in a concentration of 5 mM.
During continuously scanning with a laser confocal microscope
(Olympus FV1000, Japan), different pharmacological reagents
were added to the cell and a period of 3 min was recorded. When
the mean fluorescence became constant, the average fluorescence
intensity was used to indicate the changes of intracellular Ca
2+
during scanning period of 120,180 s. To avoid any laser-induced
changes in Ca
2+ signaling, each cell was scanned only once.
Mitochondrial membrane potential (Dym) assays
As previously described [29], 5,59,6,69-tetrachloro-1,19,3,39-
tetraethylbenzimidazolcarbocyanine (JC-1, Molecular Probes,
USA) is a kind of potentiometric dye which exhibits membrane
potential dependent-loss as J-aggregates (polarized mitochondria)
transition to JC-1 monomers (depolarized mitochondria) as
BKCa Channel and Zoledronic Acid
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Cells were loaded with JC-1 in a final concentration of 5 mg/ml
and then scanned. The Dym was monitored by determining the
relative amounts of dual emissions from mitochondrial JC-1
monomers to J-aggregates. Mitochondrial depolarization was
indicated by an increase in the green/red fluorescence intensity
ratio.
Statistical Analysis
Data are expressed as means 6 SE. A one-way ANOVA was
used to determine the significant differences in the experiments.
Post Hoc tests were used to determine where statistically significant
differences were located in apoptotic and proliferative rates among
the groups (Tukey’s test). A value of P,0.05 was considered to be
statistically significant.
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